GAITHERSBURG, Md., Feb. 29,
2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a
global company advancing protein-based vaccines with its
Matrix-M™ adjuvant, today announced it will participate in TD
Cowen's 44th Annual Health Care Conference.
Conference
Details:
|
|
|
Fireside
Chat
|
|
Date:
|
Wednesday, March 6,
2024
|
Time:
|
1:30 – 2:00 p.m.
Eastern Standard Time (EST)
|
Location:
|
Boston Marriott Copley
Place in Boston, Massachusetts
|
Moderator:
|
Brendan Smith, Ph.D.,
Vice President, Biotechnology Equity Research
|
Novavax
participant:
|
John Jacobs, President
and Chief Executive Officer
|
|
|
|
Conference
|
|
Event:
|
Investor
Meetings
|
Date:
|
Wednesday, March 6,
2024
|
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to help protect against serious infectious
diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. The Company's
portfolio includes its COVID-19 vaccine and its pipeline includes a
vaccine for COVID-19 and influenza combined. In addition, Novavax's
adjuvant is included in the University of
Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please
visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-td-cowens-44th-annual-health-care-conference-302076367.html
SOURCE Novavax, Inc.